Biomaterial Database

Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. 2021

Jian Zhang, and Qian Wu, and Ziyan Liu, and Qijie Wang, and Jiajing Wu, and Yabin Hu, and Tingting Bai, and Ting Xie, and Mincheng Huang, and Tiantian Wu, and Danhong Peng, and Weijin Huang, and Kun Jin, and Ling Niu, and Wangyuan Guo, and Dixian Luo, and Dongzhu Lei, and Zhijian Wu, and Guicheng Li, and Renbin Huang, and Yingbiao Lin, and Xiangping Xie, and Shuangyan He, and Yunfan Deng, and Jianghua Liu, and Weilang Li, and Zhongyi Lu, and Haifu Chen, and Ting Zeng, and Qingting Luo, and Yi-Ping Li, and Youchun Wang, and Wenpei Liu, and Xiaowang Qu

Translational Medicine Institute, The First People's Hospital of Chenzhou, University of South China, Chenzhou, China.

Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1-3 and individuals with COVID-19 have symptoms that can be asymptomatic, mild, moderate or severe4,5. In the early phase of infection, T- and B-cell counts are substantially decreased6,7; however, IgM8-11 and IgG12-14 are detectable within 14 d after symptom onset. In COVID-19-convalescent individuals, spike-specific neutralizing antibodies are variable3,15,16. No specific drug or vaccine is available for COVID-19 at the time of writing; however, patients benefit from treatment with serum from COVID-19-convalescent individuals17,18. Nevertheless, antibody responses and cross-reactivity with other coronaviruses in COVID-19-convalescent individuals are largely unknown. Here, we show that the majority of COVID-19-convalescent individuals maintained SARS-CoV-2 spike S1- and S2-specific antibodies with neutralizing activity against the SARS-CoV-2 pseudotyped virus, and that some of the antibodies cross-neutralized SARS-CoV, Middle East respiratory syndrome coronavirus or both pseudotyped viruses. Convalescent individuals who experienced severe COVID-19 showed higher neutralizing antibody titres, a faster increase in lymphocyte counts and a higher frequency of CXCR3+ T follicular help (TFH) cells compared with COVID-19-convalescent individuals who experienced non-severe disease. Circulating TFH cells were spike specific and functional, and the frequencies of CXCR3+ TFH cells were positively associated with neutralizing antibody titres in COVID-19-convalescent individuals. No individuals had detectable autoantibodies. These findings provide insights into neutralizing antibody responses in COVID-19-convalescent individuals and facilitate the treatment and vaccine development for SARS-CoV-2 infection.

UI	MeSH Term	Description	Entries
D003429	Cross Reactions	Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.	Cross Reaction,Reaction, Cross,Reactions, Cross
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080908	Broadly Neutralizing Antibodies	Neutralizing antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent (e.g., HIV) by targeting several epitopes.	Broad Neutralizing Antibodies,Broad Neutralizing Antibody,Broad Spectrum Antibodies,Broadly Neutralizing Antibody,Cross-Neutralizing Antibodies,Cross-Neutralizing Antibody,bnAb,bnAbs,Antibodies, Broad Neutralizing,Antibodies, Broad Spectrum,Antibodies, Broadly Neutralizing,Antibodies, Cross-Neutralizing,Antibody, Broad Neutralizing,Antibody, Broadly Neutralizing,Antibody, Cross-Neutralizing,Cross Neutralizing Antibodies,Cross Neutralizing Antibody,Neutralizing Antibodies, Broad,Neutralizing Antibodies, Broadly,Neutralizing Antibody, Broad,Neutralizing Antibody, Broadly,Spectrum Antibodies, Broad
D000084522	T Follicular Helper Cells	A specialized subpopulation of CD4+ T cells involved in formation of GERMINAL CENTER. Tfh cells are mostly located in secondary lymphoid organs, e.g., TONSIL; SPLEEN and LYMPH NODES. They are CD4 ANTIGEN; CD45 ANTIGEN; B-CELL LYMPHOMA 6 PROTEIN; CXCR5 RECEPTORS; ICOS INDUCIBLE T-CELL CO-STIMULATOR; and PD1 RECEPTOR positive.	Follicular B Helper T Cells,Follicular Helper T Cells,Tfh Cells,Tfh Cell
D000086382	COVID-19	A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.	2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402	SARS-CoV-2	A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.	2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000914	Antibodies, Viral	Immunoglobulins produced in response to VIRAL ANTIGENS.	Viral Antibodies
D054367	Receptors, CXCR3	CXCR receptors that are expressed on the surface of a number of cell types, including T-LYMPHOCYTES; NK CELLS; DENDRITIC CELLS; and a subset of B-LYMPHOCYTES. The receptors are activated by CHEMOKINE CXCL9; CHEMOKINE CXCL10; and CHEMOKINE CXCL11.	Antigens, CD183,CD183 Antigens,CXC Chemokine Receptor 3,CXCR3 Receptors,CMKBR3 Chemokine Receptors,CXC Chemokine Receptors 3,CXCR3 Receptor,Chemokine (C-C Motif) Receptor 3,Chemokine Receptors, CMKBR3,Receptor, CXCR3,Receptors, CMKBR3 Chemokine
D057134	Antibodies, Neutralizing	Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.	Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody